kabutan

Immuno-Biological Lab, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 83%, Oct-Dec Ordinary Profit Increases by 34%

Thu Feb 12, 2026 3:30 pm JST Earnings

4570 Immuno-Biological Laboratories Co., Ltd. 【J-GAAP】

Earnings Report

Immuno-Biological Laboratories Co., Ltd. <4570> [TSE Growth] announced its financial results after the market closed on February 12th (15:30). The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending March 2026 (April to December) expanded 236 million yen, an increase 82.9% compared to the same period last year. Progress toward the full-year plan of 240 million yen was 98.3%, also surpassing progress of 61.7% from the same period of the previous year.

Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the January to March period (4Q) is expected to significant drop 95.0% from the same period last year to 4 million yen.

In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit increased 33.8% from the same period last year, reaching 87 million yen. The operating profit margin jumped from 23.7% in the same period last year to 31.5%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Dec, 2023 548 10 25 20 2.2 20.0 Feb 2, 2024 J-GAAP
Apr - Dec, 2024 680 124 129 133 14.3 61.7 Feb 10, 2025 J-GAAP
Apr - Dec, 2025 742 223 236 248 26.7 98.3 Feb 12, 2026 J-GAAP
YoY +9.1% +79.8% +82.9% +86.5% +86.1%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 525 141 145 178 19.1 0 May 14, 2025 J-GAAP
Oct - Mar, 2025 Guidance 540 98 91 124 13.3 6 Nov 13, 2025 J-GAAP
YoY +2.9% -30.5% -37.2% -30.3% -30.4%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 816 104 125 186 20.1 0 May 14, 2024 J-GAAP
Mar, 2025 969 209 209 249 26.7 0 May 14, 2025 J-GAAP
Mar, 2026 Guidance 1,025 240 240 265 28.5 6 May 14, 2025 J-GAAP
YoY +5.8% +14.8% +14.8% +6.4% +6.4%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2024 236 56 65 62 6.7 23.7 Feb 10, 2025 J-GAAP
Jan - Mar, 2025 289 85 80 116 12.5 29.4 May 14, 2025 J-GAAP
Apr - Jun, 2025 211 54 57 60 6.5 25.6 Aug 8, 2025 J-GAAP
Jul - Sep, 2025 274 88 92 81 8.7 32.1 Nov 13, 2025 J-GAAP
Oct - Dec, 2025 257 81 87 107 11.5 31.5 Feb 12, 2026 J-GAAP
YoY +8.9% +44.6% +33.8% +72.6% +72.2%

Related Articles